Sort
51,593 grants matching “hepatitis”
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
$1,404,983Cindy Ann Burklow · Naprogenix, Inc · U44 · FY2022 · AA
Porphyrias Consortium
$1,404,961Robert J Desnick · Icahn School Of Medicine At Mount Sinai · U54 · FY2019 · DK
Administrative Core for the Porphyrias Consortium
$1,404,961Robert J Desnick · Icahn School Of Medicine At Mount Sinai · U54 · FY2019 · DK
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVs
$1,403,960Thomas Quinn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Mechanisms Of Drug-induced Toxicities
$1,402,533Lance R Pohl · National Heart, Lung, And Blood Institute · ZIA · FY2009 · HL
SIGNALING PATHWAYS IN CONTROL OF GROWTH AND DEVELOPMENT
$1,402,389Alan R Kimmel · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Botanical Dietary Supplements for Women's Health
$1,402,115Richard B Van Breemen · University Of Illinois At Chicago · P50 · FY2010 · AT
MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE)
$1,401,419Pamina Mae Gorbach · University Of California Los Angeles · U01 · FY2015 · DA
COLORADO ADULT AIDS CLINICAL TRIALS UNIT
$1,400,642University Of Colorado Denver · U01 · FY2002 · AI
Economic Modeling for HIV, Viral Hepatitis, STD, TB and School Health
$1,400,000Joshua A Salomon · Harvard School Of Public Health · U38 · FY2014 · PS
A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs
$1,399,895Lisa R Metsch · Columbia University Health Sciences · R01 · FY2019 · DA
Role of Tim Family Genes in Asthma and Allergic Diseases
$1,398,062Stanford University · P01 · FY2004 · AI
Determinants and Cardiovascular Consequences of Diabetes in Older Adults
$1,397,528Kenneth Jay Mukamal · Beth Israel Deaconess Medical Center · R01 · FY2011 · HL
Optimizing HIV Care in Less Developed Countries
$1,397,373Kenneth Alan Freedberg · Massachusetts General Hospital · R01 · FY2016 · AI
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit
$1,397,306Beatriz Grinsztejn · Fundacao Oswaldo Cruz · UM1 · FY2017 · AI
Characterization of human hematopoietic and endodermal progenitors derived from i
$1,396,542Darrell N. Kotton · Boston University Medical Campus · RC2 · FY2009 · HL
Stellenbosch University Clinical Trials Unit
$1,394,662Anneke Catharina Hesseling · Stellenbosch University · UM1 · FY2022 · AI
Studies of Rare Cancers
$1,393,921Louise Brinton · Cancer Epidemiology And Genetics · Z01 · FY2007 · CA
The Johns Hopkins University - Uganda Clinical Trials Unit
$1,392,989Mary Glenn Fowler · Johns Hopkins University · UM1 · FY2025 · AI
Alcohol and HIV: Biobehavioral Interactions and Intervention
$1,392,208Peter M. Monti · Brown University · P01 · FY2011 · AA
Drug Metabolizing Enzymes In Humans
$1,390,955Joyce Goldstein · National Institute Of Environmental Health Sciences · ZIA · FY2014 · ES
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
$1,389,503Christine Marie Durand · Johns Hopkins University · U01 · FY2023 · AI
San Francisco Bay Clinical Trials Unit
$1,388,627Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2016 · AI
Johns Hopkins AIDS Clinical Trials Unit
$1,388,423Charles W. Flexner · Johns Hopkins University · U01 · FY2008 · AI
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
$1,388,200Christine Marie Durand · Johns Hopkins University · U01 · FY2024 · AI